WAT Waters Corporation

Q3 2025 10-Q

Filed: Nov 4, 2025Period ending Sep 27, 2025

Health Care

Laboratory Analytical InstrumentsSEC EDGAR

Waters Corporation (WAT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 27, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $800M for Q3 FY2025, up 8% YoY from $740M; nine months revenue $2.23B, up 7% YoY from $2.09B
• Operating margin 24.0% Q3 FY2025 vs 28.5% YoY; nine months margin 23.8% vs 25.6% YoY, declined due to merger-related costs

+3 more insights

Risk Factors

• Newly added merger-related risk: consummation contingent on regulatory approvals, IRS ruling, shareholder approval; delay risks due to US government shutdown Oct 2025
• Updated financial risk: $4.0B new SpinCo debt plus potential $1.8B Waters Special Dividend funded by new indebtedness and 364-day bridge loan

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$800M

▲ +8.0% YoY▲ +3.7% QoQ

Net Income

$149M

▼ -7.8% YoY▲ +1.2% QoQ

Net Margin

18.6%

▼ -320bp YoY▼ -45bp QoQ

Source: XBRL data from Waters Corporation Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Waters Corporation Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Waters Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.